Metformin versus febuxostat for gout in obese non-diabetic patients
Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostate on Gouty Obese Non-Diabetic Patients
This study will test whether metformin or febuxostat better lowers uric acid and improves gout-related outcomes in obese people who do not have diabetes.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Damietta, New Damietta) |
| Trial ID | NCT06995339 on ClinicalTrials.gov |
What this trial studies
This Phase 2 interventional trial compares oral metformin with oral febuxostat in people with gout and obesity, measuring clinical and biochemical outcomes such as serum uric acid and gout flares. Participants will receive one of the two medications and be followed over the treatment period for changes in uric acid, frequency of attacks, and metabolic markers. The trial excludes people with diabetes and excludes pregnant or lactating women, and is conducted at a site in New Damietta, Egypt. The protocol text includes contradictory age and BMI statements that should be clarified before enrollment.
Who should consider this trial
Good fit: People with gout who are obese (BMI ≥30), do not have diabetes, and are not pregnant or breastfeeding are the intended participants.
Not a fit: Patients with diabetes, non-obese individuals, pregnant or lactating women, and those with drug-induced hyperuricemia are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the comparison could identify an effective treatment approach that lowers uric acid and reduces gout attacks in obese non-diabetic patients.
How similar studies have performed: Febuxostat is an established urate-lowering drug with prior success, while using metformin specifically for gout is relatively novel with limited prior evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males or females aged \< 18 years. * All patients are diagnosed to have gout with serum uric acid \< 7 mg/dl. * All patients are diagnosed to have obesity with body mass index (BMI) ≥ 30 kg/m2. Exclusion Criteria: * The presence of any type of diabetes mellitus. * Patients with drug-induced hyperuriceamia (those taking anti-TB agents, low dose aspirin, cytotoxic chemotherapy, diuretics, immunosuppressants, fructose, lactate infusion, testosterone or xylitol). * Non-obese patients with BMI \>30 kg/m2. * Pregnant or lactating women.
Where this trial is running
Damietta, New Damietta
- Mostafa Bahaa — Damietta, New Damietta, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.